Trial Profile
A Phase 2 Placebo-Controlled, Randomized, Double Blind, Adaptive Dose Trial of the Safety and Efficacy of Inhaled AZD1419 in Adults With Eosinophilic, Moderate to Severe Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2020
Price :
$35
*
At a glance
- Drugs AZD 1419 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms INCONTRO
- Sponsors AstraZeneca; Dynavax Technologies
- 18 Aug 2020 Primary endpoint (Time to Loss of control) has not been met, as per Results published in the American Journal of Respiratory and Critical Care Medicine
- 18 Aug 2020 Results published in the American Journal of Respiratory and Critical Care Medicine
- 16 Nov 2018 This study has been completed in Sweden.